INTRODUCTION
============

Neurodegenerative diseases (NDs) are assuming a growing relevance in the pathological scenario that jeopardizes human health. Since degenerative processes are closely age-related, NDs incidence is stalking the increment of life expectancy in all industrialized countries. These common and complex disorders are mainly characterized by the selective and progressive death of one or more specific neuronal populations, and an elevated number of cases is represented by Alzheimer's, Parkinson's, and Huntington's diseases (AD, PD, and HD, respectively). Although the increasing interest in exploring neurodegenerative phenomena and mechanisms has led to significant progresses, deciphering the molecular basis of NDs is far from complete. The identification of causative mutations in very rare monogenic Mendelian forms of NDs has provided only clues to interpret their pathological basis. Most of NDs forms rely on the combination of multiple genetic and environmental factors, and the onset and severity are influenced by their complex interactions ([@B14]). Thus, exclusively investigating risk factors and mutations in genes responsible of NDs monogenic forms may be reductive.

Regulatory multilayer networks affecting gene expression are emerging as relevant contributors in the etiology of human diseases, including NDs. Particularly, a growing number of studies are showing deregulation of different classes of non-coding RNAs (ncRNAs) -- microRNAs (miRNAs), long intergenic (lincRNAs) and long non-coding RNAs (lncRNAs) -- suggesting they may have a relevant impact on disease onset/progression ([@B15]). Their involvement in a variety of biological processes related to neurogenesis and neurodegeneration -- such as synaptic plasticity -- has been demonstrated ([@B48]).

Recently, and rather unexpectedly, NDs are displaying similarities at different levels with cancer. Epidemiological studies suggest an association between NDs' incidence and a reduced (or increased) risk of specific cancers, although conflicting results have been reported ([@B45]). Cancer cells go through uncontrolled divisions and show unlimited proliferative potential, whereas neurons degeneration implies progressive loss of synaptic structure or function and substantial cell death. At first glance it might seem paradoxical that a plethora of molecules may be common to both diseases, even though dramatic changes in transcriptional and post-transcriptional regulation similarly occur in both cancer cells and degenerating neurons. Accordingly, miRNAs have been reported in both conditions as key regulators, exerting their inhibiting roles either on common genes involved in cancer and neurodegeneration, either on different genes belonging to common pathways. Moreover, the same pool of miRNAs can target distinct genes involved in pathways specific of each disease ([@B13]).

Therefore, since carcinogenesis-related processes and neuronal circuits functionality involve not only common molecules, but also multiple similar regulatory mechanisms, here we hypothesize these complex disorders may also share a recently described mechanism of gene expression regulation based on miRNAs unbalance. Indeed, it has been recently demonstrated in cancer that some transcribed pseudogenes share miRNA responsive elements (MREs) with their parent genes competing for the same miRNAs ([@B47]; [@B26]; [@B57]). LncRNAs have the same ability of acting as miRNAs sponges ([@B4]; [@B52]). Since each miRNA is predicted to regulate up to hundreds of targets, altered expression of such transcripts -- named competitive endogenous RNAs (ceRNAs) -- may disrupt the equilibrium of available miRNAs, in turn modifying mRNAs abundance. Given such considerations, we speculate that ceRNA mechanism, demonstrated in cancer, may also be involved in NDs etiology.

Therefore, to evaluate the potential impact of ceRNA-mediated regulation of gene expression in NDs, we independently analyzed pseudogenes and their parent genes, with evidence of differential expression in AD, PD, and HD, disclosing predicted miRNAs binding sites common to pseudogene/gene pairs. Similarly, we identified a restricted pool of miRNAs targeting lncRNAs differentially expressed in such diseases. Our analysis suggests these deregulated non-coding transcripts (both pseudogenes and lncRNAs) may act as ceRNAs. Thus, we propose a new regulatory mechanism -- common to neurodegenerative and cancer processes -- may exist, and it cannot be excluded that a similar regulatory network may also underlie other human complex diseases.

miRNA FUNCTION
==============

MicroRNAs, endogenously expressed small (20--25 nucleotides) single-stranded RNAs, play crucial roles in the post-transcriptional regulation, binding a short region (seed) of mRNAs -- a complementary sequence usually located in 3′ UTRs -- and consequently leading to transcripts' degradation ([@B20]) or repressing their translation ([@B1]). Since each miRNA can target thousand of genes and, *vice versa*, each gene can be targeted by several miRNAs ([@B50]; [@B49]), such molecules are crucially implied in the fine-tuned regulation of gene expression. The proven involvement of miRNAs both in physiological and pathological processes has rapidly exposed them to the spotlight, shifting the research focus toward this class of ncRNAs^[1](#fn01){ref-type="fn"}^ ([@B43]; [@B44]; [@B35]; [@B34]; [@B37]; [@B5]; [@B18]).

miRNA IN NEURODEGENERATION
--------------------------

Understanding brain functionality has always represented a fascinating and challenging goal. Nonetheless, its complex structure and inaccessibility have made extremely difficult to study neurodegenerative processes. The identification of causative mutations explains only a little percentage of ND cases ([@B56]), whereas the alteration of gene expression levels and epigenetic changes, are emerging as new contributors to neurodegenerative disorders. Indeed, AD and PD can be seen as "gene-dosage effect" disorders: AD could be caused by gene duplication of Aβ precursor protein (*APP*; [@B46]; [@B51]), likewise α-synuclein *locus* duplication or triplication causes PD ([@B55]; [@B6]). Thus, it is reasonable to speculate that altered levels of some crucial transcripts may have a dramatic impact on neurons functionality.

Specific patterns of miRNAs expression in restricted areas have been documented in brain development and senescence ([@B38]; [@B25]). In the past few years, a growing number of reports have shown that precursor and mature miRNA transcripts and miRNA processing machinery itself (Drosha and Dicer) are disrupted during ND progression ([@B22]; [@B19]; [@B53]). In particular, gene expression analyses of sporadic PD ([@B27]) and AD ([@B33]; [@B9]) revealed that miRNA deregulation is associated to neurodegeneration, and that some miRNAs repress *APP* expression ([@B32]; [@B31]), although discordant results suggest that some experimental and technical concerns still exist (discussed in [@B11], [@B12]).

Nonetheless, the hypothesis that miRNAs are involved in ND etiology is intriguing, and understanding how, and at what extent, they contribute to neurodegenerative processes remains a crucial endpoint.

ceRNA THEORY
============

Competition among different classes of RNAs for a pool of miRNAs has been first suggested, then demonstrated, by both theoretical and experimental studies ([@B54]; [@B47]; [@B26]; [@B57]). [@B54] proposed that many computationally identified miRNA target genes might represent some "non-legitimate targets," or low-affinity miRNAs "pseudotargets." Therefore, such mRNAs would act as competitive inhibitors of miRNAs, by preventing their binding to legitimate targets.

In the wake of such hypothesis, the "competing endogenous RNAs" theory ([@B52]) has proposed the existence of legitimate *bona fide* miRNA competitors, such as demonstrated for the gene/pseudogene pairs*PTEN*/*PTENP1* and *KRAS/KRAS1P* ([@B26]; [@B57]). mRNAs can talk each other through their 3′ UTRs, and the "indirect interactions" can regulate their expression levels. Such transcribed -- but untranslated -- regions contain MREs which can regulate *in cis* the transcript levels itself and *in trans* can alter the levels of different pools of miRNAs, consequently affecting the levels of other mRNAs. Such theory, experimentally confirmed in a mouse model of melanoma ([@B26]; [@B57]), proposes that virtually all types of RNA can communicate each other through a new fascinating "biological alphabet," in which MREs are the "letters" whose different combinations may form an entire universe of "words" ([@B30]; [@B7]).

PSEUDOGENES IN NEURODEGENERATIVE DISEASES
-----------------------------------------

The contribution of ceRNAs to the availability of miRNAs in the cell has been established in cancer, and their altered expression modifies the abundance of mRNAs ([@B47]; [@B57]). Thus, understanding the contribution of ceRNAs on gene expression deregulation is particularly relevant not only in different tumors but also in other human complex diseases. In particular, since recent evidences show NDs share common altered genes, pathological mechanisms, and cellular processes with cancer, we decided to address whether ceRNAs may contribute also to NDs pathogenesis.

Therefore, we first identified the subset of genes differentially expressed in AD, PD, and HD, retrieving datasets from Gene Expression Atlas database^[2](#fn02){ref-type="fn"}^ (accession n. E-MTAB-62, E-GEOD-3790, E-GEOD-1751, E-AFMX-6, E-GEOD-7621, E-GEOD-7307, E-GEOD-20295, E-GEOD-20168, E-MEXP-2280, E-GEOD-6613). Particularly, only genes with a statistical significance of differential expression inferred from at least two independent experiments were used. As shown in **Figure [1A](#F1){ref-type="fig"}**, these datasets consisted of 17, 1002, and 5361 genes, for AD, PD, and HD, respectively. Interestingly, by using a bootstrap resampling procedure (10^5^ iterations), a significant overlap (563 genes; *p* ≪ 0.01) was disclosed between genes DE in PD and HD (**Figure [1A](#F1){ref-type="fig"}**), showing they may represent crucial genes in the etiology of neurodegeneration. Moreover, in line with the notion that common genes with proven involvement in cancer and in NDs are deregulated in both conditions ([@B39]; [@B45]; [@B13]), pathway analysis (performed using PANTHER; [@B58]) revealed a significant overlap with cancer hallmarks, including apoptosis, p53, Ras, PDGF, FGF, EGF, and MAPK signaling pathways (data not shown).

![**(A)** Venn diagram showing intersections of DE genes in all three NDs. Colored circles contain the number of genes *per* disease. **(B)** Bar graph showing the distribution of all the miRNAs binding sites (*y-*axis) identified in lncRNAs DE in HD (*x*-axis) which bind the same miRNA. Matrixes built with the lncRNAs and the restricted set of miRNAs (having common binding sites within lncRNAs sequences), for HD **(C)** and PD **(D)**. Red and blue squares indicate the presence and the absence (respectively) of miRNA binding within the target lncRNA.](fgene-03-00231-g001){#F1}

Since pseudogenes have been shown to act as miRNAs sponges in cancer we evaluated such finding also in NDs. Thus, we intersected the above-described datasets of DE genes in NDs with a full list of human pseudogenes retrieved from HUGO Gene Nomenclature Committee (HGNC) database. The intersection revealed that 49, 1, and 10 pseudogenes are DE in HD, AD, and PD, respectively. Thus, 3′ UTR sequences of pseudogenes and their parent genes were downloaded from University of California Santa Cruz (UCSC) and aligned by using BLAT algorithm to assess sequence identity. Only pseudogenes' sequences showing high homology (95--99%) were used as described below. The 3′ UTRs of some parent genes aligned outside the boundaries of their annotated cognate pseudogenes, indicated the need to revise annotations. In such cases, we used for further computational analysis the matching genomic sequences. Therefore, FASTA sequences of selected pseudogenes and the 3′ UTRs of parent genes were independently scanned for the presence of miRNA binding sites using a TargetScan perl script ([@B29]). Pseudogenes with only one miRNA binding site were excluded from further analyses. Analyzed pseudogene/gene pairs -- in each ND -- are listed in **Table [1](#T1){ref-type="table"}**.

###### 

Pseudogenes deregulated in HD, PD and AD sharing common miRNA binding sites with their parent genes.

  Pseudogene/gene pair                              miRNA family         
  ------------------------------------------------- -------------- ----- ------------
  Huntington's disease                                                   
  *BCRP2/BCR[\*](#T1fn01){ref-type="fn"}*           41             71    38 (92.7)
  *BZW1P2/BZW1[\*](#T1fn01){ref-type="fn"}*         4              50    4 (100.0)
  *CES1P1/CES1*                                     6              6     6 (100.0)
  *CHCHD2P2/CHCHD2*                                 4              5     2 (50.0)
  *COX7A2P2/COX7A2[\*](#T1fn01){ref-type="fn"}*     3              5     2 (66.7)
  *DGKZP1/DGKZ*                                     14             16    14 (100.0)
  *EEF1A1P5/EEF1A1[\*](#T1fn01){ref-type="fn"}*     9              64    8 (88.9)
  *EIF2S2P4/EIF2S2*                                 6              33    6 (100.0)
  *ETF1P1/ETF1*                                     24             59    19 (79.2)
  *FABP5P1/FABP5*                                   3              2     2 (66.7)
  *FAM108A3P/FAM108A1*                              6              7     6 (100.0)
  *FAM115B/FAM115A[\*](#T1fn01){ref-type="fn"}*     76             76    74 (97.4)
  *GBP1P1/GBP1[\*](#T1fn01){ref-type="fn"}*         39             33    24 (61.5)
  *HIGD1AP14/HIGD1A[\*](#T1fn01){ref-type="fn"}*    19             56    14 (73.7)
  *HMGA1P4/HMGA1[\*](#T1fn01){ref-type="fn"}*       2              36    1 (50.0)
  *HMGB1P1/HMGA1[\*](#T1fn01){ref-type="fn"}*       42             36    29 (69.0)
  *HMGB1P10/HMGB1*                                  15             48    13 (86.7)
  *HMGB1P5/HMGB1*                                   14             48    13 (92.9)
  *HMGN1P36/HMGN1*                                  11             11    10 (90.9)
  *HMGN2P3/HMGN2*                                   12             24    12 (100.0)
  *HNRNPA3P1/HNRNPA3*                               53             118   5 (9.4)
  *HSD17B7P2/HSD17B7*                               7              9     6 (85.7)
  *HTR7P1/HTR7*                                     35             43    17 (48.6)
  *MT1P2/MT1G[\*](#T1fn01){ref-type="fn"}*          2              4     2 (100.0)
  *MT1P2/MT1H[\*](#T1fn01){ref-type="fn"}*          2              5     2 (100.0)
  *NANOGP8/NANOG*                                   18             17    17 (94.4)
  *NSUN5P1/NSUN5*                                   15             39    12 (80.0)
  *PI4KAP2/PI4KA*                                   7              7     5 (71.4)
  *POU5F1P4/POU5F1*                                 7              9     6 (85.7)
  *PPP1R2P3/PPP1R2[\*](#T1fn01){ref-type="fn"}*     58             55    38 (65.5)
  *PTENP1/PTEN[\*](#T1fn01){ref-type="fn"}*         23             91    21 (91.3)
  *RBBP4P4/RBBP4*                                   13             147   11 (84.6)
  *RBMS1P1/RBMS1[\*](#T1fn01){ref-type="fn"}*       15             52    15 (100.0)
  *RHOQP2/RHOQ[\*](#T1fn01){ref-type="fn"}*         52             93    48 (92.3)
  *RP9P/RP9*                                        16             19    15 (93.8)
  *RPLP0P6/RPLP0[\*](#T1fn01){ref-type="fn"}*       2              2     1 (50.0)
  *S100A11P1/S100A11[\*](#T1fn01){ref-type="fn"}*   6              5     3 (50.0)
  *SKP1P1/SKP1[\*](#T1fn01){ref-type="fn"}*         25             35    18 (72.0)
  *TLK2P1/TLK2*                                     20             64    19 (95.0)
  *VDAC1P1/VDAC1[\*](#T1fn01){ref-type="fn"}*       21             26    20 (95.2)
  *VEZF1P1/VEZF1[\*](#T1fn01){ref-type="fn"}*       64             85    53 (82.8)
  *YWHAZP3/YWHAZ[\*](#T1fn01){ref-type="fn"}*       11             54    8 (72.7)
  *ZFAND6P1/ZFAND6*                                 15             16    14 (93.3)
  **Parkinson's disease**                                                
  *CHCHD2P2/CHCHD2*                                 4              5     2 (50.0)
  *HSD17B7P2/HSD17B7*                               7              9     6 (85.7)
  *NSUN5P1/NSUN5*                                   15             39    12 (80.0)
  *NSUN5P2/NSUN5*                                   13             39    11 (84.6)
  *PHC1P1/PHC1*                                     47             46    46 (87.9)
  *PPP1R2P3/PPP1R2*                                 58             55    38 (65.5)
  *RBMXP2/RBMX*                                     26             59    22 (84.6)
  **Alzheimer's disease**                                                
  *CRYBB2P1/CRYBB2*                                 6              5     5 (83.3)

Genes DE in the related disease.

This analysis revealed that pseudogenes deregulated in HD, AD, and PD, share (on average) about 80% of miRNA binding sites with their parent genes, suggesting these highly expressed -- but untranslated -- transcripts may represent novel ceRNAs, possibly subtracting a relevant fraction of common miRNAs to the physiological regulation of their parent genes. Interestingly, our analysis revealed that two pseudogenes, *PTENP1* and *POU5F1P4* -- recently described as ceRNAs in cancer ([@B47]) -- are differentially expressed in NDs and share a very significant fraction of MREs (about 90%) with their parent genes (see **Table [1](#T1){ref-type="table"}**).

Our findings strengthen the hypothesis of a novel convergent ceRNA-mediated regulatory mechanism, underlying both cancerogenesis and neurodegenerative process. We cannot exclude that over-expression of such pseudogenes may subtract a pool of miRNAs not only to their parent genes, but they may also contribute to a more global gene deregulation, accounting for disease etiology. Systematic analysis of DE pseudogenes in NDs, and further targeted functional studies are needed to confirm these observations.

LncRNA IN NEURODEGENERATIVE DISEASES
------------------------------------

Long non-coding RNAs are a numerous class of non-protein coding transcripts longer than 200 nucleotides. Prior studies and, more recently, transcriptomic analyses by Next Generation Sequencing (NGS), indicate the lncRNAs are as abundant as mRNAs ([@B3]; [@B21]; [@B2]). Given their proven key role in many biological processes and their restricted expression pattern in specific brain regions ([@B36]), it is reasonable to speculate they may be altered in NDs and be involved in their etiology ([@B23]; [@B41]). Furthermore, the hypothesis that lncRNAs could sequester miRNAs and act as ceRNAs ([@B4]; [@B52]), suggests a novel fascinating role for them in NDs.

In light of these considerations, we examined lncRNAs differentially expressed in NDs, similarly to pseudogenes analysis. By using an *in silico* approach and a list of human lncRNAs obtained from HGNC database, we identified 31, 4, and 1 lncRNAs DE in HD, PD, and AD, respectively. Since they are alternatively spliced, we retrieved the sequences corresponding to all splicing transcripts (222, 5, and 1 Ensembl transcripts for HD, PD, and AD, respectively) and we scanned them for the presence of miRNA binding sites. In AD, the only lncRNA significantly DE was *BACE1-AS*whose role in Alzheimer's pathogenesis has been already reported ([@B16], [@B17]). Our analysis revealed *BACE1-AS*has predicted binding sites for 18 miRNAs, some of with proven association to AD, such as let-7, mir-127, mir-93a ([@B5]; [@B28]), suggesting it may be an intriguing ceRNA candidate in AD etiology. The distribution of MREs within lncRNAs DE in HD (**Figure [1B](#F1){ref-type="fig"}**) and PD was evaluated in order to identify the lncRNAs sharing a pool of common MREs. By using a bootstrap resampling procedure we created random sets of lncRNAs that underwent the same miRNA analysis. We measured their MREs distributions observing they significantly differ from our observations (*p* \< 0.05).

Moreover, given the large number of lncRNAs DE in HD and PD, we used random datasets also to set two thresholds on the number of lncRNAs sharing common MREs, whose values were 10 for HD and 2 for PD. Such thresholds were used to select -- for further analysis -- a restricted pool of miRNAs whose seeds match at least 10 and 2 lncRNAs analyzed for HD and PD, respectively. Thus, we built two matrixes (one for disease) with all the lncRNAs altered in a specific disease and its related stringent set of miRNAs (**Figures [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}** for HD and PD, respectively).

Although predictive and computationally-based, our analysis shows that lncRNAs deregulated in NDs share a pool of MREs, suggesting such long untranslated transcripts may represent a previously undetected source of competitive binding sites also for brain-specific miRNAs, thus potentially acting as ceRNAs.

PERSPECTIVES AND CONCLUSIONS
============================

Growing interest in understanding the basis of neurodegenerative processes has led to significant steps forward, even though many underlying molecular aspects are still unknown. The identification of disease-causing mutations in Mendelian forms of NDs and genome-wide associations studies have only partially provided satisfactory explanation to disease pathogenesis, whereas gene expression studies, and the analysis of their regulation, are currently giving a significant contribution to better understand NDs. Particularly, miRNAs and other ncRNAs are showing relevant roles in neural cell plasticity as well as in neurodegenerative processes ([@B24]).

In cancer, recent evidences show that untranslated transcripts, pseudogenes, and presumably lncRNAs, named ceRNAs, compete for a pool of miRNAs acting as endogenous sponges and regulating parent genes and other mRNAs ([@B47]; [@B26]; [@B52]; [@B57]). Such findings are likely to have broader implications for other diseases and cellular processes, largely beyond the regulation of few genes in cancer.

Therefore, given that NDs and cancer share common causative genes and altered signaling molecular pathways, even considering the crucial role of miRNAs in neurogenesis- and cancerogenesis-related processes, we have proposed and computationally predicted both pseudogenes and lncRNAs may be involved in the etiology of AD, HD, and PD, acting as ceRNAs.

In such NDs, independent analysis of DE lncRNAs, pseudogenes, and parent genes, revealed they contain a huge number of shared MREs, potentially representing miRNAs sponges. It suggests that ceRNAs may represent the rule, rather than the exception, also in the etiology of NDs. Our observations indicate that a ceRNA-based regulatory mechanism might be shared between neurodegenerative and cancerous processes, and we cannot exclude that similar complex regulatory networks may also underlie other human complex diseases. However, studying pseudogenes is challenging due to the high sequence identity with their parent genes, and genome-wide expression studies may report conflicting results about pseudogenes expression. The introduction of NGS, particularly of RNA sequencing, is substantially contributing to overcome some technological challenges for the transcriptome analysis ([@B8]; [@B40]; [@B11], [@B10]) also for studying expressed pseudogenes. We believe this technology will increasingly help researchers to encrypt the novel ceRNAs code, giving an incredible boost to understand this new "language."

Finally, targeted functional studies are clearly needed to validate and confirm this predictive study, even though we believe that ceRNAs have traced a novel revolutionary route in the landscape of human genetics.
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